Arbutus Biopharma Corporation (NASDAQ: ABUS) announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares closed down 8% at $8.29 after UBS adjusted its price target to $7 from $4, while reaffirming a Neutral rating.
Gossamer Bio, Inc. (NASDAQ: GOSS) finalized a private placement financing agreement for as much as $250 million linked to seralutinib development, featuring a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares closed up 21% at $6.28 after the company priced a $2.0 million registered direct offering of 307,692 shares, adding modest near-term capital.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002, giving Jupiter a psychedelic neuropsychiatric asset.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) will merge with Ambros Therapeutics in an all-stock transaction to form Nasdaq-listed Ambros Therapeutics, shifting focus to neridronate for CRPS-1.
1. IRAN/MARKETS: Bessent to Unveil "Greatest Financial Offensive Ever Marshaled" Against Iran; Gold Hits a Three-Month High as Oil and Yields Ease
Philip Morris International (NYSE:PM) announced that, through its non-US affiliates, it has entered into a contract manufacturing arrangement for combustible cigarettes with Philip Morris USA, an operating company of Altria (NYSE:MO). Altria separately confirmed the arrangement, describing it as intended to enhance the efficiency …
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares ticked higher in pre-market trading after the company announced that its investigational drug imsidolimab received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis, a severe and potentially life-threatening inflammatory skin disease. The designation marks …